Express News | Tracer Biotechnologies Announces Multi-Year Project With AstraZeneca
Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95
TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN)
AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial
Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
loading...
守株待鹅 : Goddess, which one are you Bullish on?